Are you feeling called to be one of them? We invite you to apply for the Entrada Scholars Program: a two-week, on-campus, college-level experience that helps you grow as a leader and thrive as a first ...
Pink slips have followed the green light at Entrada Therapeutics. Weeks after the FDA lifted a more than two-year-long hold, the biotech has set out plans to reduce its workforce by 20% and prioritize ...
Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that the Company granted an aggregate of 12,990 restricted stock units (“RSUs”) to two newly-hired non-executive employees under the Company’s ...
BOSTON - Entrada Therapeutics , Inc. (NASDAQ:TRDA) received authorization from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) to initiate a Phase 1/2 clinical trial for its ...
Maha Radhakrishnan, MD · GlobeNewswire Inc. BOSTON, June 03, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced the appointment of Maha Radhakrishnan, M.D., to its ...
Entrada Therapeutics has debuted with a $59 million series A and a plan to deliver biologic therapies intracellularly to treat rare and fatal monogenic diseases. The Boston-based company will start by ...
BOSTON, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biotechnology company aiming to transform the lives of patients by establishing Endosomal Escape Vehicle (EEV™) ...
Entrada Therapeutics plans to initiate ELEVATE-44-201 trial for ENTR-601-44 in Duchenne muscular dystrophy by Q2 2025. Entrada Therapeutics, Inc. announced that it has received regulatory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results